TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HbSC disease~* Hemoglobin level between 8 and 12.5 g/dL~* At least one vaso-occlusive event (e.g., pain, acute chest syndrome) in the 12 months prior to study entry. An episode of pain is defined as the occurrence of pain in the extremities, back, abdomen, chest, or head that lasts at least 2 hours; requires a visit to a hospital, emergency room, clinic, or provider's office; and is not explained except by SCD. Acute chest syndrome is defined as a new pulmonary infiltrate on a chest x-ray associated with a fever (greater than 38.5° C), tachypnea, wheezing, cough, or chest pain.~* Regular compliance with comprehensive care~* In a steady disease state and not experiencing an acute complication of SCD (i.e., no hospitalization, pain event, or episode of acute chest syndrome within the 1 month prior to study entry)~Exclusion Criteria:~* Previous transfusion with remaining hemoglobin A greater than 10%~* Previous treatment with hydroxyurea within the last 3 months~* Previous treatment with magnesium within the 3 months prior to study entry (including vitamins containing magnesium)~* Poor compliance with previous treatment regimens~* Liver dysfunction (SGPT greater than twice the upper limit of normal) within the 1 month prior to study entry~* Kidney dysfunction (creatinine greater than or equal to 1.0 mg/dL for participants less than 18 years of age; greater than or equal to 1.2 mg/dL for participants 18 years of age or older) within the 1 month prior to study entry~* Pregnant~* Ten or more hospital admissions for pain in the 12 months prior to study entry~* Daily use of narcotics~* Treatment with any investigational drug in the 3 months prior to study entry~* Less than 3% red blood cells with density greater than 41 g/dL (as measured by the ADVIA 120 system)~* Positive HIV test~* Other long-term illness or disorder other than SCD that could adversely affect performance in the study (e.g., tuberculosis)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Pills and Placebo Liquid (Type: PLACEBO_COMPARATOR): None
- Hydroxyurea Pills and Placebo Liquid (Type: ACTIVE_COMPARATOR): None
- Placebo Pills and Magnesium Pidolate Liquid (Type: ACTIVE_COMPARATOR): None
- Hydroxyurea Pills and Magnesium Pidolate Liquid (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically and/or cytologically confirmed cervical cancer, meeting 1 of the following criteria:~  * Stage IVB disease~ * Recurrent disease~ * Persistent disease~* Patients previously treated with chemoradiotherapy as initial therapy must demonstrate disease progression~* Measurable disease by physical exam or radiographic studies~* Not amenable to chemoradiotherapy or surgery~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-2~Life expectancy~* At least 6 months~Hematopoietic~* WBC ≥ 3,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* SGOT and SGPT ≤ 2 times upper limit of normal~* Bilirubin ≤ 1.5 mg/dL~Renal~* Creatinine ≤ 1.5 mg/dL OR~* Creatinine clearance ≥ 50 mL/min~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known HIV positivity~* No active infection~* No medical condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon~* No other concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* At least 3 months since prior chemoradiotherapy (6 weeks for patients experiencing disease progression after completion of initial chemoradiotherapy)~* No other prior chemotherapy~Endocrine therapy~* No concurrent hormonal therapy for cancer~Radiotherapy~* See Disease Characteristics~* See Chemotherapy~* Recovered from prior radiotherapy~* No concurrent radiotherapy~Surgery~* Recovered from prior surgery~* No concurrent surgery for cancer~Other~* No prior retinoids~* No other concurrent anticancer therapy~* No other concurrent experimental agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b (Type: EXPERIMENTAL): * Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~* Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~* Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Camel Milk Consumption Decrease The Efficacy Of Midazolam For Sedation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Arab origin~* Female 18 -48 years of age~* BMI \< 37 kg/m2~* All ovarian stimulation protocols~Exclusion Criteria:~* Previous oocyte retrieval at our center~* Post chemo therapy~* Illicit drug use~* Chronic pain medication~* Medication which is known to increase the activity of liver enzymes~* Any alcohol consumption~* Previous vaginal delivery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- non-camel milk consumption (Type: None): non-camel milk consumption over life time
- camel milk consumption (Type: None): camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Any infant with a birth weight 401 - 1500 grams and \< 34 weeks gestational age with an OI (mean Paw x FiO2 x 100/PaO2) \> 10 on two consecutive blood gases at least 30 minutes apart, but no more than 12 hours apart.~or~* Infants \> 1500 grams and \< 34 weeks gestational age will be entered in the Larger Preemie Pilot Study if they have an OI greater than or equal to 15 on two consecutive blood gases at least 30 minutes apart, but no more than 12 hours apart.~* Infants requiring assisted ventilation with a diagnosis of RDS/HMD, pneumonia and/or sepsis, aspiration syndrome, idiopathic pulmonary hypertension, or suspected pulmonary hypoplasia associated with PROM and/or oligohydramnios.~* Greater than or equal to 4 hours after one dose of surfactant.~* Less than or equal to 120 hours of age.~* All infants must have an indwelling arterial line.~Exclusion Criteria~* Any infant in whom a decision has been made not to provide full treatment (e.g. chromosomal anomalies or severe birth asphyxia).~* Known structural congenital heart disease, except patent ductus arteriosus and atrial-level shunts.~* Infants with any major abnormality involving the respiratory system such as congenital diaphragmatic hernia, tracheoesophageal fistula or cystic fibrosis.~* Any bleeding diathesis considered to be clinically significant or thrombocytopenia with platelet count \< 50,000.~* Prior enrollment into a conflicting clinical trial such as the Neonatal Network Surfactant CPAP trial.Inclusion Criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Hours
- Healthy Volunteers: f

Study Arms:
- Inhaled Nitric Oxide (Type: EXPERIMENTAL): Inhaled Nitric Oxide
- Placebo (Type: ACTIVE_COMPARATOR): Inhaled Oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For Patients who Completed CAT-1004-201 or CAT-1004-301:~Inclusion Criteria:~* Written consent/assent by patient and/or legal guardian as per regional and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements~* Completion of either CAT-1004-201 or CAT-1004-301~Exclusion Criteria:~* In the Investigator's opinion, unwilling or unable for any reason to complete all study assessments and laboratory tests and comply with scheduled visits, administration of drug, and all other study procedures~For Siblings of Patients who Completed CAT-1004-201 or CAT-1004-301:~Inclusion Criteria:~* Written consent/assent by patient and/or legal guardian as per regional and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements~* A sibling of a patient who completed either CAT-1004-201 or CAT-1004-301~* Diagnosis of DMD based on a clinical phenotype with increased serum creatine kinase (CK) and documentation of mutation(s) in the dystrophin gene known to be associated with a DMD phenotype~* Followed by a doctor or medical professional who coordinates Duchenne care on a regular basis and willingness to disclose patient's study participation with medical professionals~Exclusion Criteria:~* Use of oral corticosteroids at screening; use of inhaled, intranasal, and topical corticosteroids is permitted~* Use of another investigational drug, idebenone, or dystrophin-focused therapy within 4 weeks. Exception: Patients who are currently on or plan to initiate treatment with approved oligonucleotide exon-skipping therapies, and expected to continue treatment throughout the study, will be eligible~* Use of the following within 4 weeks prior to Day 1: immunosuppressive therapy, anticoagulants, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil, pimozide, quinidine, sirolimus or tacrolimus~* Use of human growth hormone within 3 months prior to Day 1~* Other prior or ongoing significant medical conditions

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: EXPERIMENTAL): Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Antibiotics After Aspiration in ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the ICU within the last 24 hours, or with a witnessed aspiration event in the last 24 hours while in the ICU~* Radiographic findings on chest x-ray or CT deemed by the treating ICU team to be consistent with aspiration (e.g. dependent infiltrates or intraluminal airway debris)~* Clinical history consistent with possible aspiration (e.g. cardiac arrest, found unconscious, or with a witnessed aspiration event).~Exclusion Criteria:~* Already received 3 or more doses of any antibiotic since hospital presentation, unless the last dose was greater than 1 week before enrollment~* Requires antibiotic therapy for the treatment of other infections~* Patient comfort measures only at time of screening~* Currently participating in other trials using investigational drugs or interventions~* Currently pregnant~* Currently a prisoner~* The consenting party (patient or their legally authorized representative) is unable to understand or read English at a fifth-grade level.~* 2 or more of the following are present at the time of screening:~* White blood cell count: ≥ 11.0~* Temperature ≥ 38.0C (100.4F)~* Purulent secretions~* S/F (pulse oximetry saturation to FiO2) ratio ≤ 215

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antibiotics (Type: EXPERIMENTAL): 5 days of empiric antibiotics selected from a guideline-appropriate regimen. Alternate agents may be selected by the treating team if allergies or other patient factors mandate, but are still recommended for a 5 day course. Supportive care including oxygen and ventilation can be offered ad libitum.~Options include ceftriaxone, Augmentin, cefepime, vancomycin, levofloxacin.
- Control (Type: NO_INTERVENTION): No initial antibiotic therapy unless clinical picture changes or worsens. Supportive care including oxygen and ventilation can be offered ad libitum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Starter Formula With Synbiotics on Stool Microbiota in Infants After Normal or Caesarean Section Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy newborn infant from HIV positive mother~* Full term infant (more or equal to 37 weeks gestation; less or equal to 42 weeks gestation)~* Age of infant 3 days at the time of enrollment~* Birth weight between 2500 and 4500 grams~* Singleton birth~* The infant's mother has elected to feed their child exclusively with a milk formula from birth~* Informed consent from the parent or legal guardian~Exclusion Criteria:~* Congenital illness or malformation that may affect normal growth~* Significant pre-natal and / or post-natal disease~* Newborns who have received antibiotics during the first 3 days of life~* Newborns whose parents / caregivers cannot be expected to comply with the study protocol~* Newborns currently participating in another clinical trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: t

Study Arms:
- Infant starter formula with synbiotics (Type: EXPERIMENTAL): Infant starter formula with synbiotics
- Infant formula without synbiotics (Type: ACTIVE_COMPARATOR): Infant formula without synbiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must give written informed consent before any assessment is performed.~* Outpatients ≥ 18 years of age, male or female.~* Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction (EF =\< 35%) and elevated BNP.~* Patients must be on an ACEI or an ARB at a stable dose of at least enalapril 10 mg/d or equivalent for at least 4 weeks.~* Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks.~Exclusion Criteria:~* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.~* History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drugs.~* Previous history of intolerance to recommended target doses of ACEIs or ARBs~* Known history of angioedema.~* Requirement of treatment with both ACEIs and ARBs.~* Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy).~* Symptomatic hypotension and/or a SBP \< 100 mmHg.~* Estimated GFR \< 30 mL/min/1.73m2 as measured by the simplified MDRD formula~* Serum potassium \> 5.2 mmol/L.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 (Type: EXPERIMENTAL): single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
- Enalapril (Type: ACTIVE_COMPARATOR): single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sildenafil on Choroidal Thickness in AMD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has been diagnosed with AMD (362.50-52) or healthy controls as detailed above~* at least 65 years of age~* capable and willing to provide consent~Exclusion Criteria:~* History of previous photodynamic therapy (PDT), intravitreal corticosteroid injection, macular focal laser photocoagulation, panretinal photocoagulation, ocular ionizing irradiation, transpupillary thermotherapy, or any vitreoretinal surgeries~* History of central serous chorioretinopathy, polypoidal choroidal vasculopathy, uveitis, or diabetic retinopathy~* History of amblyopia, glaucoma, retinal detachment, retinal dystrophy, ocular trauma, ocular tumor, proliferative retinopathy, or epiretinal membrane with distortion of central macula~* History of myopia of more than 6 diopters (D) spherical equivalent~* History of uncontrolled diabetes or hypertension~* Current use of oral phosphodiesterase type 5 inhibitors (including sildenafil, avanafil, lodenafil, mirodenafil, tadalafil, vardenafil, udenafil, zaprinast)~* Current use of systemic corticosteroids~* Any contraindication to sildenafil use, including history of cardiovascular disease or stroke, hepatic cirrhosis (Child-Pugh A and B), severe renal impairment (creatinine clearance \<30mL/min), anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease), disorders predisposing to priapism (e.g. sickle cell anemia, multiple myeloma, or leukemia), or current use of organic nitrates, alpha-blockers, or potent cytochrome P450 3A4 inhibitors

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: ACTIVE_COMPARATOR): Healthy individuals \>65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
- AMD patients (Type: EXPERIMENTAL): Age-related macular degeneration (AMD) patients \>65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symmetrical painful diabetic peripheral neuropathy~Exclusion Criteria:~* History of hypersensitivity, allergy or contraindication to opioids and acetaminophen~* Confounding painful conditions~* Significant vascular disease~* History or risk of seizure~* Chronic disease that might effect drug absorption, distribution, metabolism, or excretion~* Female subjects who are being pregnant or breastfeeding~* Evidence or history of alcohol, medication, or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A GRT3983Y (Type: EXPERIMENTAL): Participants randomly assigned to receive GRT3983Y.
- B Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues